GlassScriptPhysician profile
Caitlin M Clarkin
NPI 1174001614
$2,719.67
in general payments reported to CMS, 2019-2025
25 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.13 · 2022: $166 · 2023: $329 · 2024: $649 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.37 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $465.60 | 2021-2024 | Unid_pass, Mazor X System, Catalyft Pl Expandable Interbody System |
| Janssen Biotech, INC. | $340.74 | 2024-2025 | Tremfya, Talvey, Darzalex |
| Incyte Corporation | $181.04 | 2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $153.15 | 2022-2025 | Lynparza |
| Jazz Pharmaceuticals INC. | $150.64 | 2025 | |
| Kite Pharma, INC. | $139.88 | 2025 | Yescarta |
| Adc Therapeutics America, INC. | $139.19 | 2025 | |
| Daiichi Sankyo INC. | $136.67 | 2024-2025 | Enhertu, Injectafer |
| Teva Pharmaceuticals USA, INC. | $132.00 | 2024 | Uzedy |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Libtayo |
| Beone Medicines USA, INC. | $114.15 | 2025 | Tevimbra |
| Geron Corporation | $105.61 | 2025 | Rytelo |
| Sobi, INC | $78.70 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $78.57 | 2024 | |
| Mannkind Corporation | $77.91 | 2023 | Afrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $71.94 | 2024-2025 | Ogsiveo |
| Abbvie INC. | $31.84 | 2025 | |
| Merck Sharp & Dohme LLC | $28.96 | 2024 | Keytruda |
| Caris Mpi, INC. | $27.05 | 2025 | Mi Cancer Seek |
| Eisai INC. | $26.20 | 2025 | |
| Array Biopharma INC | $26.08 | 2025 | Braftovi |
| Pharmaessentia USA Corporation | $25.37 | 2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $22.67 | 2024 | Onivyde |
| Astellas Pharma US INC | $21.27 | 2025 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $19.45 | 2025 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Clarkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.